recurrent cardiovascular events. 4 This suggests that controlled inflammation and immune response might be the prerequisites for appropriate cardiac wound healing after MI. Manipulating regulatory T-cell (Treg) function and abundance is an attractive therapeutic strategy for attenuating cardiac remodeling via modulating immune responses. 5 However, systemically activated Tregs could cause considerable off-target effects, induce immunosuppression, and increase susceptibility to infection, 6 highlighting the need for more selective anti-inflammatory approaches within the desired time window to achieve effective suppression of injurious processes without negatively interfering with the reparative response. 7 Thus, a better understanding of the molecular and cellular mechanisms underlying the inflammatory response after MI and development of alternative agents that ensure optimal temporal and spatial regulation of the inflammatory response are urgently required.
IL-35, which consists of an EBI3 (Epstein-Barr virus-induced gene 3) subunit and an IL-12A (also known as p35) subunit, belongs to the heterodimeric IL-12 family of cytokines originally identified in Tregs. 8 Although it shares components with IL-12 (composed of p35 and p40) and IL-27(composed of p28 and Ebi3), IL-35 has distinctly different immunologic functions, exhibiting potent immunosuppressive effects comparable to those of IL-10 and TGF (transforming growth factor)-β1. 9 The IL-35R (IL-35 receptor) involves 3 different dimers composed of IL-12Rβ2 and GP130, including the IL12Rβ2:GP130 heterodimer, IL12Rβ2:IL12Rβ2 homodimer, and GP130:GP130 homodimer. 10 The binding of IL-35 to its receptor leads to the activation of members of the Janus kinase family and phosphorylation of members of the STAT (signal transducer and activator of transcription) family, which can then initiate the transcription of target genes.
Studies investigating the precise role of the IL-35 signaling pathway in cardiac remodeling after MI are lacking. Therefore, this study aimed to examine the effects of IL-35 in myocardial inflammation, wound healing, and survival in a mouse model of MI.
Methods
The data, analytic methods, and study materials are available to other researchers on reasonable request. Additional Materials and Methods are in the Online Data Supplement.
Statistical Analysis
Results were presented as mean±SEM. Data normality was determined by Shapiro-Wilk test. Comparisons between 2 groups were made using Student t test, whereas the data obtained from multiple groups were compared using ANOVA followed by Bonferroni post hoc analysis. Non-normal data were analyzed by Mann-Whitney U test or Kruskal-Wallis test with Dunn multiple comparison. A P value <0.05 was considered significant. GraphPad Prism 5.0 (Graph Pad Prism Software, Inc, San Diego, CA) and SPSS 15.0 for Windows (SPSS, Inc, Chicago, IL) were used for statistical analysis.
Results

IL-35 Expression Increases After MI
The results of quantitative polymerase chain reaction and Western blotting illustrated the kinetics of IL-35 subunits (EBI3 and p35) expression in mouse heart tissue at different time points post-MI. Compared with sham-operated mice, EBI3 increased post-MI, peaking on day 5, whereas p35 peaked on day 1; levels of both subunits remained elevated 
Novelty and Significance
What Is Known?
• Postinfarct healing and optimal scar formation play crucial roles in the strengthening of the infarct tissue and preventing adverse remodeling.
• The reparative process after acute myocardial infarction (MI) is characterized by the emergence of Ly6C low macrophages, which promote healing.
• IL (interleukin)-35, a member of the heterodimeric IL-12 family of cytokines, participates in a variety of immune responses.
What New Information Does This Article Contribute?
• IL-35 plays an important role in scar formation, thereby protecting against cardiac rupture and improves survival after MI.
• Pharmacological inhibition of IL-35 suppresses the accumulation of Ly6C low macrophages.
• IL-35 increases CX3CR1 (C-X3-C motif chemokine receptor 1) and TGF (transforming growth factor)-β1 production in macrophages and subsequently promotes the survival of Ly6C low macrophage and extracellular matrix deposition.
• IL-35 is a new member of the IL-12 family of cytokines, originally identified in Tregs. However, its role in cardiac remodeling after MI is unknown. In this study, we show that the expression of IL-35 increases in the infarcted region and it is mainly expressed in Tregs after MI. IL-35 inhibition impairs infarct healing and aggravates cardiac remodeling after MI. Moreover, we found that IL-35 mediates and improves macrophages survival, which in turn orchestrates cardiac tissue remodeling and improves cardiac function. IL-35 activated the transcription of CX3CR1 and TGF-β1 in macrophages by inducing the phosphorylation of STAT1 (signal transducer and activator of transcription family) and STAT4 and subsequently promoted extracellular matrix deposition. These results suggest that IL-35 may be a promising early therapeutic intervention to prevent adverse cardiac remodeling and rupture post-MI.
for the duration of the 14 days post-MI ( Figure 1A and 1B).
To more critically evaluate the combination of EBI3 and p35, we used antibodies to coimmunoprecipitate EBI3 and p35 in heart tissues after MI. The p35 antibody successfully immunoprecipitated EBI3 in heart tissues on day 3 after MI and vice versa ( Figure 1C ). Based on ELISA analysis, levels of IL-35 were significantly increased in heart lysates on day 3 post-MI ( Figure 1D ). Immunofluorescence staining showed that EBI3 and p35 were mainly expressed in Tregs in mouse hearts on day 5 post-MI ( Figure 1E and 1F). Moreover, a minor population of macrophages expressed EBI3 and p35, whereas dendritic cells and neutrophils did not express EBI3 or p35 ( Figure 1F and Online Figure I ). Figure 1G and Figure 1 . IL (interleukin)-35 levels were increased in the heart after myocardial infarction (MI). A, EBI3 (Epstein-Barr virus-induced gene 3) and p35 expression levels were analyzed at different time points after MI (n=7-8). *#P<0.05 vs respective sham group. B, EBI3 and p35 protein levels were determined at different time points (n=6). *P<0.05 vs sham group. C, Coimmunoprecipitation (Co-IP) and Western blotting analysis of EBI3 and p35 proteins from mouse hearts at different time points after MI. D, IL-35 content in hearts was measured at different time points post-MI (n=6-7). *P<0.05 vs sham group. E, Representative immunostaining of EBI3 (red), Foxp3 (forkhead box P3; gray), p35 (green), and nuclei (4′,6-diamidino-2-phenylindole, blue) in murine hearts at day 5 post-MI. Scale bar, 50 μm. F, Quantification of EBI3-and p35-positive cells (n=6-7). *P<0.05. G, EBI3 and p35 expression levels were analyzed in regulatory T cells, macrophages, and dendritic cells isolated from hearts at day 5 post-MI (n=5-6). *P<0.05. H, Representative immunostaining of EBI3 (red), Foxp3 (gray), F4/80 (gray), CD11c (gray), p35 (green), and nuclei (4′,6-diamidino-2-phenylindole, blue). Scale bar, 10 μm. Data are expressed as mean±SEM. Data were analyzed using one-way ANOVA followed by Bonferroni post hoc analysis.
Online Figure II) . In contrast, p35 was mainly expressed in Tregs ( Figure 1G ). In addition, immunofluorescence staining of FACS-purified Tregs, macrophages, and dendritic cells demonstrated that IL-35 subunits EBI3 and p35 were mainly coexpressed in Tregs ( Figure 1H ).
IL-35 Inhibition Impairs Cardiac Function After MI
We first examined whether systemic IL-35 neutralization would impact cardiac function after MI. For anti-IL-35 treatment, we took advantage of a unique EBI3 monoclonal antibody that neutralizes IL-35 but not IL-27, the other known EBI3-containing cytokine. 8, 9, 11 Wild-type (WT) C57BL/6 mice underwent permanent left anterior descending ligation and received weekly treatment with anti-IL-35 or IgG 2b isotype ( Figure 2A ). First, we examined cardiac remodeling and dysfunction in WT and anti-IL-35-treated mice. At baseline, echocardiographic parameters in anti-IL-35-treated mice were comparable to those in WT mice (Online Table II Table II) . Furthermore, anti-IL-35-treated mice showed increased heart and lung weight/body weight ratios, indicating their compromised cardiac function on day 14 post-MI compared with that in WT mice (Online Table II ). We performed additional experiments to demonstrate anti-EBI3/IL-35 antibody specificity. EBI3 or p35 deficiency abolished the effect of IL-35 neutralization ( Figure 2C and 2D and Online Figure IIIB and IIIC).
IL-35 Inhibition Exacerbates MI-Induced Cardiac Rupture, Wall Thinning, and Healing
In comparison with control animals, the survival rate of anti-IL-35-treated mice was significantly lower on day 28 after MI (56% versus 35.56%; log-rank test; P=0.0012; Figure 3A ). The incidence of cardiac rupture-induced death was significantly higher in anti-IL-35-treated mice than in WT mice (51.11% versus 28%; P=0.0345; Figure 3B ), although heart failure rates were similar in both groups (13.33% versus 16%; P=0.78).
Masson trichrome staining revealed no difference in the gross morphology of the sham-operated hearts between WT and IL-35 inhibition mice. By contrast, 14 days after MI, IL-35 inhibition resulted in reduced wall thickness at the infarct area compared with that observed in WT mice, although the infarct size was similar between the 2 groups ( Figure 3C ). Interestingly, the infarct size was significantly higher in ruptured hearts in mice with IL-35 inhibition than in WT mice ( Figure 3D ). The collagen volume fraction, as detected by Picrosirius red staining in the infarct areas, was significantly decreased in mice with IL-35 inhibition compared with that in WT mice at 14 days after MI ( Figure 3E ). Furthermore, IL-35 inhibition significantly downregulated the level of hydroxyproline, a major component of collagen ( Figure 3F ). However, myocardial fibrosis in the noninfarct area did not differ significantly between the WT and IL-35 inhibition groups (Online Figure IV) .
IL-35 Inhibition Reduces Wound Healing and Scar Formation After MI
To elucidate the mechanisms underlying cardiac rupture, myocardial wound healing parameters and myofibroblast differentiation were analyzed after MI. At day 5 and day 14 post-MI, the expression of α-SMA (α-smooth muscle actin), collagen I, and collagen III in the infarcted heart was significantly decreased in mice subject to IL-35 inhibition than in WT mice ( Figure 4A ). Moreover, protein levels of α-SMA and collagen I were significantly lower in IL-35 inhibition mice than in control mice at day 5 and day 14 post-MI ( Figure 4B and Online Figure VA and VB). Additionally, immunofluorescence staining was performed to assess the expression of these proteins at day 5 and day 14 post-MI and demonstrated that the expression levels of these proteins were significantly lower in mice with IL-35 inhibition than in WT mice ( Figure 4C and Online Figure VC) . Furthermore, we used a specific marker for mouse cardiac fibroblasts, mEF (mouse embryonic fibroblast)-SK4, to isolate fibroblasts from the ischemic myocardium, with a maintenance of the functional phenotype 12 ( Figure 4D ). Cardiac fibroblasts exhibited decreased expression of α-SMA, collagen I, and collagen III in mice subject to IL-35 inhibition compared to that in WT mice ( Figure 4E and 4F). To determine whether EBI3 knockout Tregs reduce wound healing, WT mice underwent permanent left anterior descending ligation and were treated with a single adoptive transfer of WT Tregs, EBI3 knockout Tregs, or PBS (Online Figure VIA) . The results showed that expression levels of α-SMA, collagen I, and collagen III were significantly decreased in mice with adoptive transfer of EBI3 knockout Tregs compared with that in mice with transfer of WT Tregs at day 14 post-MI ( Figure 4G ). Moreover, adoptive transfer of EBI3 knockout Tregs resulted in increased infarct size and reduced wall thickness at the infarct area compared with that observed in mice with WT Tregs (Online Figure  VIB) . The collagen volume fraction, as detected by Picrosirius red staining in the infarct areas, was significantly decreased in mice with adoptive transfer of EBI3 knockout Tregs compared with that in adoptive transfer of WT Tregs at 14 days after MI (Online Figure VIC) .
Myocardial angiogenesis has been reported to play a crucial role in wound healing and cardiac remodeling, and therefore, levels of angiogenesis were investigated by CD31 staining at day 5 and 14 post-MI. The results of quantitative polymerase chain reaction and immunostaining demonstrated that CD31 was not significantly altered in mice treated with anti-IL-35 antibody compared with its expression in WT mice at day 5 and day 14 post-MI (Online Figure VIIA and VIIB). Furthermore, terminal deoxynucleotidyl transferase-mediated dUTP (deoxyuridine triphosphate)-biotin nick-end labeling staining was performed to detect cardiomyocyte apoptosis at day 5 and day 14 after MI. No significant differences were observed in apoptosis between mice with and without IL-35 inhibition (Online Figure VIIC) . In addition, we examined the effect of IL-35 inhibition on cardiomyocyte contractile response. IL-35 inhibition triggered overt anomalies in cardiomyocyte contractile properties as evidenced by dampened peak-shortening and reduced maximal velocities of shortening (+dL/dt; Online Figure VIID ).
IL-35 Inhibition Reduces Cardiac Recovery by Decreasing Ly6C low Macrophage Survival
The IL-35R is composed of IL-12Rβ2 and GP130 subunits. Because cardiac fibroblasts play an important role in cardiac inflammation and repair after MI, we examined the expression of IL-12Rβ2 and GP130 in fibroblasts. Unexpectedly, IL-12Rβ2 was not expressed in NIH/3T3 fibroblasts or cardiac fibroblasts (Online Figure VIIIA) , and treatment with anti-IL-35 antibody did not have significant effects on α-SMA or collagen expression in cardiac fibroblasts treated with TGF-β1, suggesting that IL-35 was not directly involved in extracellular matrix protein deposition (Online Figure VIIIB) + monocytes/macrophages were sorted from infarcted hearts in mice ( Figure 5A ). Notably, total numbers of infiltrated monocytes/macrophages in the infarct and border zone were significantly reduced in mice subject to IL-35 inhibition starting from 5 days after left anterior descending artery ligation compared with those in WT mice ( Figure 5B and 5C Figure 5B ). Moreover, IL-35 inhibition results in decreased macrophage survival in the heart after MI ( Figure 5D ). Consistent with a survival defect, higher amounts of cleaved caspase-3 were detected in macrophages sorted from infarcted hearts treated with anti-IL-35 (Online Figure IXA) . However, anti-IL-35 treatment had no significant effect on proliferation of macrophages as determined with bromodeoxyuridine (Online Figure IXB and IXC) . Furthermore, IL-35 inhibition did not influence circulating Ly6C low or Ly6C high monocytes (Online Figure IXD and IXE) . In addition, monocyte adoptive transfer experiment confirmed that anti-IL-35 treatment did not have an overt influence on Ly6C high monocyte differentiation in the circulation or in infarcted hearts (Online Figure  X) . Expression of the Ly6C low macrophage surface marker CX3CR1 (CX3C chemokine receptor 1) and of TGF-β1 in the infiltrating macrophages was significantly reduced in the IL-35 inhibition group ( Figure 5E ), whereas expression of the CX3CR1 ligand, CX3CL1 (C-X3-C motif chemokine ligand 1), was not altered in the hearts of mice subject to IL-35 inhibition mice (Online Figure XI) . Researchers have performed detailed lineage tracing, flow cytometry, and transcriptomic analyses to define cell surface markers for cardiac macrophages in the mouse, including CD45, CD64, MHC II, and CCR2 (C-C motif chemokine receptor type 2).
14 On deeper inspection of cardiac macrophages, and using previously published gating schemes, we were able to distinguish between recruited Ly6C high monocytes and CD64 + Ly6C low macrophages, which were further distinguished by MHC II and CCR2 expression. Interestingly, IL-35 inhibition significantly downregulated CD45 + CD11b + CD64 + Ly6C low MHC II low CCR2− macrophages ( Figure 5F and 5G). To examine whether cell survival contributes to cardiac CCR2 − macrophage maintenance, we performed immunostaining for CD68, CCR2, and terminal deoxynucleotidyl transferasemediated dUTP-biotin nick-end labeling. IL-35 inhibition induced a decrease in CD68 + CCR2 − macrophages survival ( Figure 5H ).
Given that anti-IL-35 inhibited TGF-β1 expression in reparative Ly6C low macrophages, we tested the effect of anti-IL-35 treatment on α-SMA and collagen I expression in vitro. Functionally, Ly6C high and Ly6C low macrophages are similar to M1-and M2-type macrophages in the context of inflammation. 15, 16 Macrophages can be differentiated in vitro toward M2 polarization by IL-4. Indeed, TGF-β1 expression was diminished in cultured cardiac macrophages treated with anti-IL-35 antibody and stimulated with IL-4 ( Figure 6A ). We then exposed cardiac fibroblasts to anti-IL-35 antibody directly or to cell culture medium collected from cardiac macrophages incubated with anti-IL-35 antibody. Cardiac -9) . B, Collagen I and α-SMA protein expression at day 5 post-MI in the scar tissue isolated from wild-type (WT) and anti-IL-35-treated mice. C, Immunohistochemical analyses of α-SMA, collagen I, collagen III (Scale bars,100 μm) in the heart tissue at day 5 post-MI (n=7). D, Gating strategy for fibroblasts in the infarcted heart. E, Gene expression of α-SMA, collagen I, and collagen III in fibroblasts isolated from infarcted tissue at day 5 after MI (n=6). *P<0.05 vs WT MI; #P<0.05 vs WT Sham. F, Representative immunostaining of collagen I (green), α-SMA (red), and nuclei (DAPI [4′,6-diamidino-2-phenylindole], blue). Scale bar, 20 μm. G, Immunohistochemical analyses of α-SMA, collagen I, collagen III (Scale bars, 100 μm) in the infarcted heart tissue at day 14 post-MI (n=7) from mice treated with PBS, WT regulatory T cells (Tregs), or EBI3 (Epstein-Barr virus-induced gene 3) knockout Tregs. *P<0.05 vs WT Tregs; #P<0.05 vs PBS. Data are expressed as mean±SEM. Data in C and G were analyzed using Student t test. Data in A and E were analyzed using 2-way ANOVA followed by Bonferroni post hoc analysis. Col1a1 indicates collagen type I alpha 1 chain; Col3a1, collagen type III alpha 1 chain; and SSC, side scatter.
fibroblasts exhibited decreased expression of extracellular matrix proteins after incubation with anti-IL-35 antibodyexposed macrophage medium ( Figure 6B and 6C ). In contrast, direct exposure of cardiac fibroblasts to anti-IL-35 antibody did not change α-SMA or collagen I expression ( Figure 6B and 6C) .
IL-35 Deficiency Inhibits CX3CR1 and TGF-β1 Expression in Macrophages Through Phosphorylated STAT1-STAT4
Ly6C low macrophage survival during inflammation, including that post-MI, promotes reparative processes, such as extracellular matrix formation. 17 , 18 We detected a decreased expression + macrophages and dramatic downregulation of TGF-β1 expression in peritoneal macrophages isolated from anti-IL-35-treated mice challenged by zymosan ( Figure 6D and Online Figure XIIA and XIIB). To investigate the mechanism by which IL-35 regulates CX3CR1 expression, we used specific antibodies to block GP130 or IL12Rβ2 in peritoneal macrophages isolated from mice challenged by zymosan. GP130 blockade inhibited the phosphorylation of STAT1, but not of STAT4, and significantly inhibited IL-35-mediated CX3CR1 and TGF-β1 upregulation ( Figure 6E and Online Figure XIIC and XIID) . In contrast, blockade of IL12Rβ2 inhibited the phosphorylation of STAT4, but not + CD64 + peritoneal macrophages in mice treated with vehicle or anti-IL-35 antibody after a zymosan challenge. Cx3cr1 expression in peritoneal macrophages was quantified and compared (n=7). E, Macrophages were pretreated with or without anti-IL12Rβ2 antibody (2 µg/mL) or anti-GP130 antibody (100 ng/mL) for 30 min, and then IL-35 (100 ng/mL) was added to culture for another 24 h. The cells were subjected to Western blotting assays (n=4). F, Schematic illustration of predicted SBEs (STAT1/STAT4 binding elements) in the promoters of murine Cx3cr1 and Tgfb1 genes. S denotes SBE. G, ChIP (chromatin immunoprecipitation) analysis of RAW264.7 cells pretreated with or without IL-35 (100 ng/mL) for 90 min. Chromatin was immunoprecipitated with anti-STAT1 or anti-STAT4 antibodies and then subjected to polymerase chain reaction analysis. H, ChIP:reChIP analysis of RAW264.7 cells prepared as in G; chromatin was first immunoprecipitated with anti-STAT1 or anti-STAT4 antibody and then immunoprecipitated again with anti-STAT4 (S1→S4) or anti-STAT1 (S4→S1). *P<0.05 vs Control; #P<0.05 vs Isotype. Data in D were analyzed using Student t test. Data in A and B were analyzed using 2-way ANOVA followed by Bonferroni post hoc analysis. SSC indicates side scatter.
of STAT1, and significantly inhibited CX3CR1 and TGF-β1 expression ( Figure 6E and Online Figure XIIC and XIID) . Moreover, this IL-35-mediated CX3CR1 and TGF-β1 expression was completely abrogated when GP130 and IL12Rβ2 were blocked simultaneously ( Figure 6E and Online Figure  XIIC and XIID). Taken together, these results suggest that IL-35 stimulates CX3CR1 expression through the pSTAT1 (phosphorylated STAT1)-pSTAT4 branch of the signaling cascade.
Through the EPD (Eukaryotic Promoter Database) website, 2 and 1 potential SBEs (STAT1/STAT4 binding elements) were predicted in the promoters of the murine Cx3cr1 (S1-S2) and Tgfb1 (S1′) genes, respectively ( Figure 6F ). To determine whether IL-35 directly regulates Cx3cr1 and Tgfb1 transcription through pSTAT1-pSTAT4, we performed ChIP (chromatin immunoprecipitation) and ChIP:reChIP analyses to investigate the binding of STAT1/ STAT4 to the Cx3cr1 and Tgfb1 promoters. Primers were designed to target these sites by ChIP assay with anti-STAT1 and anti-STAT4 antibodies. As shown in Figure 6G and Online Figure XIIE , IL-35 induced marked binding of STAT1 and STAT4 to S1 and S1′ but not S2. Next, we performed a ChIP: reChIP analysis to confirm this finding. In this assay, the product of ChIP with an anti-STAT1 antibody was subjected to a second ChIP with an anti-STAT4 antibody and vice versa. As expected, IL-35 induced the binding of the pSTAT1-pSTAT4 heterodimer to S1 and S1′ ( Figure 6H and Online Figure XIIF) . Taken together, these results showed that IL-35 regulates CX3CR1 and TGF-β1 expression in macrophages by binding to the GP130:IL12Rβ2 receptor and then activating the pSTAT1-pSTAT4 heterodimer.
IL-35 Reduces Cardiac Rupture and Promotes Wound Healing and Scar Formation After MI
We found that the survival rate was higher in IL-35-treated mice than in WT mice at day 28 after MI (53.85% versus 74%; log-rank test, P=0.0159; Figure 7A ). The incidence of cardiac rupture-induced death was significantly higher in WT mice than in IL-35-treated mice (32.69% versus 14%; P=0.0354; Figure 7B ), although heart failure (diagnosed by the presence of pleural effusion and lung congestion) rates were similar in both groups (13.46% versus 12%; P=0.82). 19 At day 5 and day 14 post-MI, the expression of α-SMA, collagen I, and collagen III in the infarcted heart was markedly higher in mice subject to IL-35 treatment than in WT mice ( Figure 7C ). Additionally, immunohistochemical analyses were performed to assess the expression of α-SMA, collagen I, and collagen III at day 5 and 14 post-MI and demonstrated that the expression levels of these proteins were significantly higher in IL-35-treated mice than in WT mice ( Figure 7D and Online Figure XIIIA) . The collagen volume fraction, as detected by picrosirius red staining in the infarct areas and hydroxyproline ELISA assay, was significantly higher in IL-35-treated mice than in WT mice 14 days after MI ( Figure 7E and 7F) . Cardiac fibroblasts exhibited increased expression of α-SMA and collagen I in mice subject to IL-35 treatment compared with that in WT mice ( Figure 7G and 7H). Moreover, total numbers of infiltrated macrophages in hearts were significantly increased in mice subject to IL-35 treatment after left anterior descending artery ligation compared with those in WT mice ( Figure 8A through 8C) , through an increase in CD45 + CD11b + F4/80 + Ly6G -Ly6C low macrophages ( Figure 8A through 8C) . Immunofluorescence staining demonstrated that IL-35 treatment significantly decreased the rate of macrophages apoptosis ( Figure 8D ). Moreover, IL-35 significantly downregulated the expression of cleaved caspase-3 in macrophages sorted from infarcted hearts ( Figure 8E) . Expression of the Ly6C low macrophage surface marker CX3CR1 and of TGF-β1 was significantly increased in the IL-35 treatment group ( Figure 8F) Figure 8G and 8H) . To examine whether cell survival contributes to cardiac CCR2 − macrophage maintenance, we performed immunostaining for CD68, CCR2, and terminal deoxynucleotidyl transferasemediated dUTP-biotin nick-end labeling. IL-35 induced an increase in CD68 + CCR2 − macrophages survival ( Figure 8I ).
Discussion
Current pharmaceutical interventions aiming to slow the progression of atherosclerosis focus almost exclusively on reducing plasma levels of cholesterol. However, clinical and experimental data also indicate a critical role of inflammation in the pathogenesis of atherothrombosis. The CANTOS study (Canakinumab Anti-inflammatory Thrombosis Outcome) has helped to move the inflammatory hypothesis of coronary artery disease forward scientifically. Therefore, a better understanding of inflammation in coronary artery diseases would aid in the development of novel drugs for the treatment of coronary artery disease. In this study, we identified IL-35 and its downstream Ly6C low macrophage cytokine TGF-β1 as central coordinators of the wound healing process after MI. We further revealed that IL-35 inhibition leads to impaired scar formation and aggravated LV remodeling, resulting in increased risk of cardiac rupture and worse cardiac function in mice with experimental MI. Therefore, the manipulation of this immune axis may assist in the prevention of adverse events in ischemic cardiomyopathy.
IL-12p35 associates as a heterodimer with either EBI3 or p40 to create the cytokines IL-35 and IL-12, respectively.
9 IL12p35 deficiency limited acute myocardial infarction-induced cardiac injury owing to increased angiogenesis and reduced inflammation. 20 IL-12 is a proinflammatory cytokine produced by dendritic cells and macrophages, whereas IL-35 is a novel inhibitory cytokine that is produced by Tregs and contributes to their suppressive activity. 8, 21 It is clear that the phenotype of IL-12p35 deficiency needs to be reevaluated, as it may be milder than anticipated owing to the contrasting activities of IL-35 and IL-12. 8 More precise functions of IL-35 and IL-12 should be examined under different pathophysiological conditions by using specific antibodies. In this study, we demonstrated that the IL-35 subunits EBI3 and p35 are significantly upregulated in the infarcted zone at the early phase post-MI, suggesting that these molecules may be involved in ventricular remodeling. Further analysis revealed that IL-35 inhibition promotes cardiac rupture and remodeling by inhibiting myofibroblast activation and collagen deposition. The protein and mRNA levels of collagen I and III, as well as α-SMA, were significantly downregulated in MI mice after IL-35 inhibition, indicating a lower level of myofibroblast differentiation in IL-35-inhibited mice. Post-MI, activated myofibroblasts migrate into the damaged tissue, express extracellular matrix proteins in abundance, leading to the formation of a collagenous scar that is crucial for the prevention of infarct expansion and LV rupture. 2 However, IL-35 inhibition did not affect angiogenesis, although it is an important process involved in granulation tissue formation. Compared with control MI mice, IL-35-treated MI mice showed increased collagen expression within the scar and decreased rates of LV rupture. These results suggest that the IL-35 signaling pathway specifically affects the healing process by modulating extracellular matrix deposition and the transition of fibroblasts to myofibroblasts.
The local inflammatory environment orchestrates macrophage infiltration, proliferation, survival, and polarization. Two main subsets of monocytes/macrophages have been documented in mice: Ly6C high proinflammatory monocytes/ macrophages migrate into injured tissues and express high levels of C-C chemokine receptor CCR2, and these cells scavenge debris and secrete proinflammatory cytokines and matrix-degrading proteases, which contribute to myocardial injury. 17 The alternatively activated Ly6c low monocytes/macrophages are able to produce and secrete inhibitory mediators, such as IL-10 and TGF-β1, and these cells represent negative regulators of inflammation and promote reparative processes, such as angiogenesis and extracellular matrix formation. 22 In this study, we observed that IL-35, mainly expressed in Tregs and to a lesser extent in macrophages, plays a crucial role in post-MI healing. Although we revealed that IL-35 subunits EBI3 and p35 are mainly expressed on Tregs and to 24, 25 It is to note that future studies using CCR2 GFP transgenic mice might be helpful to validate the observed results in this study. In agreement with our observations, cardiac macrophages are able to expand through improved survival, suggesting that improving macrophage survival may be a key strategy for regulating macrophage density in ischemic myocardium. 3 In the complex environment of the infarcted heart, the spatially and temporally regulated expression of a variety of cytokines, chemokines, and growth factors might all be able to affect macrophage survival. 5, 26 We speculate that although the regulation of macrophage survival by IL-35 might not be the only mechanism, it constitutes a crucial contribution to the beneficial effects of therapeutic and most likely also physiological Treg activation after MI. Therefore, further studies are needed to explore the effects of IL-35 on CCR2 − MHC II low macrophages survival, molecular profiles, and their functional roles in the healing process after MI. IL-35 differs from other cytokines of the IL-12 family in that it can induce a downstream signaling cascade by binding to 3 receptor dimers composed of GP130:IL12Rβ2, GP130:GP130, or IL12Rβ2:IL12Rβ2. Binding to these receptors subsequently activates 3 different signal transduction cascades: pSTAT1-pSTAT4, pSTAT1-pSTAT1, or pSTAT4-pSTAT4, respectively. 10 Then, the pSTAT dimers translocate to the nucleus to initiate the transcription of target genes. Previous studies have demonstrated that IL-35 signals through GP130:IL12Rβ2 to activate the pSTAT1-pSTAT4 heterodimer, which binds to the EBI3 and p35 genes and initiates selfactivation. 10 Nevertheless, in another study, IL-35 promoted ICAM1 (intercellular adhesion molecule 1) transcription through only one branch of its signal transduction pathway (pSTAT1-pSTAT1 homodimer). 27 In the present study, however, we showed that IL-35 binds to the GP130:IL12Rβ2 heterodimer, activates the pSTAT1-pSTAT4 heterodimer, and then initiates the transcription of TGF-β1 and CX3CR1, which, in turn, contributes to mediate macrophage survival. 18, 28 These findings indicate that IL-35 likely activates different target genes via different signaling pathways. Elucidation of the IL-35 signaling pathways may further contribute to the development of IL-35-targeted therapy; however, the mechanism by which IL-35 is upregulated post-MI and by which mechanism the IL-35 select what signaling chain for activation of different target genes requires further clarification.
The interaction between immune cells and cardiac fibroblasts during wound healing has gained a considerable amount of attention recently. 29, 30 The interaction between activated Tregs and macrophages likely constitutes an amplification loop that creates an anti-inflammatory micromilieu and promotes de novo extracellular matrix deposition in infarcted myocardium. 5, 6 In this study, we demonstrated that Tregderived IL-35 contributes to the wound healing of the infarct area by promoting Ly6C low macrophage survival and TGF-β1 production, which are considered to have beneficial effects in several immune-mediated diseases, as well as atherosclerosis and vascular inflammation. 31 In conclusion, we demonstrated that IL-35 can promote scar formation in the ischemic heart. IL-35 orchestrates the myocardial inflammatory response in the post-MI phase, increases Ly6C low macrophage survival in the infarcted area, and promotes the production of TGF-β1. Through indirect effects on cardiac fibroblasts in the infarcted area, IL-35 enhances cardiac repair and decreases ventricular rupture and the mortality rate.
